Last C$0.74 CAD
Change Today -0.02 / -2.63%
Volume 427.2K
As of 3:59 PM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

theratechnologies inc (TH) Snapshot

Open
C$0.78
Previous Close
C$0.76
Day High
C$0.83
Day Low
C$0.70
52 Week High
03/2/15 - C$0.83
52 Week Low
12/3/14 - C$0.33
Market Cap
45.1M
Average Volume 10 Days
233.1K
EPS TTM
C$-0.14
Shares Outstanding
61.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for THERATECHNOLOGIES INC (TH)

Related News

No related news articles were found.

theratechnologies inc (TH) Related Businessweek News

No Related Businessweek News Found

theratechnologies inc (TH) Details

Theratechnologies Inc., a biopharmaceutical company, develops and commercializes therapeutic peptide products. The company’s lead product is EGRIFTA (tesamorelin for injection), an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in the United States. It also focuses on commercializing EGRIFTA in Latin America, Africa, the Middle East, Europe, Russia, South Korea, Taiwan, Thailand, and certain central Asian countries. Theratechnologies Inc. also has TH1173, a second-generation GRF peptide that has completed preclinical studies in its product pipeline. The company was founded in 1993 and is headquartered in Montréal, Canada.

Founded in 1993

theratechnologies inc (TH) Top Compensated Officers

Chief Executive Officer, President and Non-In...
Total Annual Compensation: C$376.0K
Vice President of Finance
Total Annual Compensation: C$170.0K
Vice President of Legal Affairs and Secretary
Total Annual Compensation: C$233.0K
Vice President of Pharmaceutical Development
Total Annual Compensation: C$211.5K
Senior Vice President of Scientific Affairs a...
Total Annual Compensation: C$265.0K
Compensation as of Fiscal Year 2013.

theratechnologies inc (TH) Key Developments

Theratechnologies Announces Commercialization Agreement for EGRIFTA (Tesamorelin for Injection) in Europe

Theratechnologies Inc. announced that it has concluded an agreement with AOP Orphan Pharmaceuticals AG (AOP) for the distribution and commercialization of EGRIFTA in several European countries. Under the terms of the agreement, AOP will be responsible to conduct all regulatory activities to obtain marketing authorizations for EGRIFTA on a country-by-country basis in the territory. Prior to receiving such marketing authorizations, AOP intends to distribute EGRIFTA in the territory through Named Patient Sales Programs. Theratechnologies will be responsible for the manufacture of EGRIFTA and its supply to AOP at a predetermined transfer price. Moreover, AOP will pay royalties on net sales of EGRIFTA over a certain price level. The AOP agreement further provides for a milestone payment upon obtaining marketing authorizations, pricing and reimbursement approvals in countries totaling a certain number of inhabitants, as well as milestone payments upon reaching certain levels of cumulative net sales of EGRIFTA in the territory. An upfront payment of EUR 150,000 is associated with the execution of the Agreement. Including that upfront payment, milestone payments could potentially reach a combined total of EUR 3 million. The term of the Agreement varies on a country-by-country basis and extends for seven years from the first sales of EGRIFTA in each country or February 25, 2025, whichever is later.

Theratechnologies Inc. Announces Audited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended November 30, 2014

Theratechnologies Inc. announced audited consolidated earnings results for the fourth quarter and full year ended November 30, 2014. Consolidated revenue for the twelve months ended November 30, 2014 was $6,732,000 compared to $7,553,000 fiscal 2013. Prior to the closing of the EMD Serono Termination Agreement on May 1, 2014, revenues were mainly composed of net sales of EGRIFTATM to EMD Serono for re-sale, royalties received from EMD Serono on U.S. sales to customers, and research services, which included milestone payments and the amortization of the initial payment received from EMD Serono. Net loss for the year of $10,541,000 Consolidated revenue for the three months ended November 30, 2014 amounted to $2,663,000 compared to $1,246,000 for the comparable period of 2013. Revenue generated from net sales for the three months ended November 30, 2014 was $2,657,000 compared to $311,000 in the comparable period in fiscal 2013. In the three months ended November 30, 2014, the use of cash in operating activities amounted to $2,416,000 compared to $1,404,000 in the comparable period of fiscal 2013.

Theratechnologies Inc. to Report Fiscal Year 2014 Results on Feb 26, 2015

Theratechnologies Inc. announced that they will report fiscal year 2014 results at 8:30 AM, US Eastern Standard Time on Feb 26, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TH:CN C$0.74 CAD -0.02

TH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TH.
View Industry Companies
 

Industry Analysis

TH

Industry Average

Valuation TH Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THERATECHNOLOGIES INC, please visit www.theratech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.